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A quantitative approach to the distress caused by symptoms in patients
treated with radical radiotherapy
AJ Munro and S Potter
Department ofRadiotherapy, St Bartholomew's Hospital, West Smithfield, London ECIA 7BE, UK.
Summary A computerised self-assessment instrument was used to capture data on the distress caused by
symptoms in 110 patients treated with radical radiotherapy. Patients selected symptoms from a list of 34
problems and then quantified the distress associated with each problem using a linear Analogue selfassessment
(LASA)-type scale. The test instrument was feasible: 90% of assessments were completed in under 14 min.
There was a significant increase in tiredness and significant decrease in anxiety and worries about the family,
during treatment. Menopausal symptoms and post-surgical problems were important causes of distress in the
patients with breast cancer. When the area under the curve method was used to quantify distress in the patients
with breast cancer, difficulty concentrating, pain and sleep disturbances emerged as significantly troublesome
problems. Computerised self-assessment may have a useful role in quantifying the distress caused by treatment
with radiotherapy.
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Patients treated with radiotherapy have physical and
psychological symptoms related both to the underlying
disease and to the treatment. The distress caused by these
symptoms can only be assessed adequately by the patients
themselves (Slevin et al., 1988). Inability to measure
accurately and feasibly the symptomatic distress experienced
by patients undergoing treatment with radiotherapy has, to
an extent, hindered the rational scientific development of
clinical radiotherapy. Factors influencing tumour control
have been carefully analysed, but the price paid for that
control, in terms of subjective distress, has largely been
ignored. Prescribing practices vary widely (Priestman et al.,
1989) and largely reflect previous training and/or institutional
dogma (Maher, 1991). Insufficient quantitative information
on what patients actually experience means that it is very
difficult to incorporate patients' views into decisions about
the optimal scheduling of treatment. Many of the problems
experienced by patients during radiotherapy may be
preventable or might be amenable to treatment. However, it
is not possible to ameliorate, or to advise patients about,
unrecognised problems. If we wish to improve the quality of
care for patients then we need to know their views as to what
the problems actually are: which symptoms are important
and which symptoms are less distressing.
There are no standard instruments that address the specific
concerns of patients during treatment with radiotherapy.
There is an abundant literature on the assessment of 'quality
of life' (Aaronson et al., 1993; Ganz et al., 1992; Selby et al.,
1984; Olschewski et al., 1994), but these instruments do not
deal in detail with the particular symptoms that radiation
treatment might itself produce. The tendency has been to
concentrate on collapsed global indices. Radiotherapy causes
quite specific symptoms, distress from which will probably
impinge upon overall quality of life, but which will only be
one aspect of a much broader and more complex domain.
Collapsed indices are of little help in these circumstances. In
order to improve standards, we need to be able to focus on
the distress caused by specific problems in patients under-
going a course of radiotherapy treatment. In the absence of
any standard instrument we have had to design our own test
instrument.
In a previous study (Munro et al., 1989) we showed that it
was possible to capture useful information on the distress
caused by symptoms in patients being treated with radio-
therapy. The technique used was adapted from the method
originally described by Coates et al. (1983). The disadvantage
ofthe method was that it was too time-consuming for routine
use in clinical practice. Each assessment took around 30 min,
and the data entry procedures were cumbersome. Based on
this previous experience, we designed a computerised test-
instrument that avoids some of the previous problems. We
wanted an instrument that would be feasible for routine use,
reasonably comprehensive, reliable and responsive. Respon-
siveness was a particularly important criterion as we wished
to be able to track changes in levels of distress during and
immediately after a course of treatment.
This paper presents data from over 400 assessments,
performed with the computerised test instrument, from 110
patients treated with radical radiotherapy for cancers of the
head and neck, bronchus and breast.
Patients and methods
All consecutive outpatients attending for radiotherapy under
the care of one consultant were selected for entry into the
study. The patients were treated on 6 MV linear accelerators.
Three groups of patients were studied:
(1) Patients with stage I or II breast cancer receiving post-
operative radiotherapy to the breast (after local excision)
or to the chest wall (after mastectomy). The majority of
patients were treated with 40 Gy in 15 fractions over 3
weeks to tangential fields only; a minority received an
additional boost of 10 Gy in five fractions over 1 week.
The cervicoaxillary chain was not treated as nearly all
patients had full axillary clearance.
(2) Patients with head and neck cancer treated with radical
radiotherapy. All patients were treated in a shell for
immobilisation and doses ranged from 50 to 55 Gy in 20
fractions over 4 weeks.
(3) Patients treated with more than five fractions of
radiotherapy for localised lung cancer. The standard
regimen for these patients was 22.5 Gy in five fractions
over 1 week using parallel opposed fields to the chest
followed by a 2-3 week gap. Patients who had tolerated
the first phase of treatment well and who had not
developed clinical or radiological evidence ofprogressive
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March 1996disease were treated with a second phase of treatment
22.5 Gy in five fractions over 1 week using a two- or
three-field plan to avoid the spinal cord.
The only patients excluded from the study were patients
who were unable to comprehend written English. Accrual
was from 1st April 1994 to 1 December 1994.
The assessment schedule for each group of patients is
summarised in Table I; the schedule chosen for each group
represents a compromise between the need to assess patients
at the likely time of maximum treatment-related morbidity
and the desire to keep extra attendances at hospital to a
minimum.
Assessment procedure
All patients were asked about the same basic set of
symptoms, the core symptoms, and in addition there was a
specific set of additional symptoms for each diagnostic group
(Appendix). The system was completed automated. After
entering their hospital number, for identification, the patient
was shown a series of symptoms on the computer screen.
Each symptom appeared within a box in the centre of the
screen, and at the bottom of the screen was the question
'Does this symptom trouble you Y or N?'. If the patient
answered N the program moved on to the next symptom; if
the patient answered Y a further screen was shown with the
request 'Please indicate how much you are troubled by
(symptom)'. Underneath was a box with a highlight within it
which could move horizontally. There were 15 possible
positions for the highlight within the box. The left end of
the box was labelled 'not at all' and the right end of the box
was labelled 'unbearably'. The patient was asked to place the
highlight within the box at the position that corresponded to
the level of distress produced by that particular symptom.
The procedure was directly analogous to the completion of a
LASA scale. The position chosen by the patient was recorded
automatically and the assessment then moved on to the next
question.
The list of symptoms was compiled on the basis of:
previous experience; informal conversations with patients;
consultations with staff within the department. An open
request, 'Please enter any other problems that concern you,
but about which we have not asked you, in the box below',
was also included within the questionnaire.
Additional questions were added to the basic symptom
inventory in order to permit some assessment of the validity
of the approach. The McGill present pain index (PPI) and
automated LASA scales for pain, overall quality of life
[analogous to the Uniscale (Selby et al., 1984)] and disruption
due to treatment were added as well as the Hospital Anxiety
and Depression (HAD) Scale (Zigmund and Snaith, 1983).
The computer's internal time clock was used to record the
duration of the assessment; the duration of the HAD
assessment was separately recorded.
The assessments were carried out under the supervision of
the research nurse (SP) in a private room. The nurse was
available to help with any difficulties patients might have
understanding the questions or the procedure; the nurse was
seated so that patients were aware that their responses could
not be seen directly by her. If, at the end of the session,
patients had any problems or questions, these were dealt
with.
Programs, data, analysis and statistics
The test instrument was written using an expert system
(Crystal, Intelligent Environments), which then automatically
exported responses to a standard relational database (Dbase
for Windows, Borland). There was therefore no separate data
entry procedure: the patients had directly entered the data
and there was no editing of responses. The data were
exported to Excel (Microsoft v5.0) for graphical presentation
and spreadsheet analysis. The statistics were performed using
Stata (Stata Corporation).
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A symptom that was not troubling the patient was scored
as zero. Symptoms that were causing problems were scored
from 1 to 15 using the LASA bar scale. For each symptom it
is possible in any group of patients to obtain a mean score
for that symptom. An alternative method of analysis is to
ignore the scores and simply record symptoms as being
present or absent. The information has been analysed both
ways.
Area under the curve (AUC) measurements could be
obtained for each symptom for each individual patient. The
calculation was performed according to the method described
by Matthews et al. (1990). The area under the curve for
symptom score plotted against time was estimated as the sum
of the measurements:
(t2 -ttl)(yl + y2)/2
where t2-t1 is the interval between the measurements and y,
and Y2 are the symptom scores at the two time points.
Problems with the scheduling of interviews meant that
complete data sets were not available for all patients. The
problem of missing data was handled in three different ways:
(1) only complete data sets were analysed;
(2) zero was substituted for all missing values;
(3) missing values were imputed using linear regression.
Correlation between the various components of the
instrument has been assessed using Kendall's tau. The
changes in responses over time have been assessed using the
Wilcoxon matched-pairs signed-ranks test as well as the non-
parametric test for trend described by Cuzick (1985).
Results
A total of 110 patients were eligible for the study: there were
72 patients with breast cancer, average age 53 years (range
31-74 years); there were 24 patients with lung cancer,
average age 71 years (range 46-81 years); there were 14
patients with head and neck cancer, average age 63 years
(range 32-82 years).
Feasibility
All patients were able to complete the computerised
questionnaire. There were no problems with non-compliance
or technical malfunction. The average duration of each
assessment was 10.0 min (95% CI 7.8-12.2), the median
Table I Assessment schedules for the patients according to type of
cancer and treatment
Allpatients
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duration was 7.3 min and 90% of assessments were
completed in under 14 min. There was evidence of a possible
learning effect: the average duration of first interviews was
12.0 min (95% CI 10.0-14.), whereas the mean duration of
the fourth interviews was 7.2 min (95% CI 6.6-7.7). The P-
value for this difference is 0.0001 (z=6.67) using the
Wilcoxon signed-ranks matched-pairs test. It took an
average of 2.3 min (95% CI 2.2-2.4) to administer the
Hospital Anxiety and Depression scale in its computerised
form; 90% of the HAD assessments were completed in less
than 6.5 min.
Comparison between components of the computerised
questionnaire and standard measures
The correlation matrix in Table II shows values for Kendall's
tau and P-values for those elements of the test instrument for
which standard tests were available. The data come from the
initial assessments on all 110 patients in the study. The
reasonable correlation for appropriate comparisons (pain, the
separate LASA scale for pain and the PPI) and, conversely,
the poor correlations for inappropriate comparisons (for
example, depression and the PPI) suggests that the
components of the test instrument have both criterion
validity and discriminant validity (Nunnally, 1978).
Core questions (all 110 patients)
The following 13 symptoms were selected by less than 30% of
patients; sickness, weight loss, constipation, hoarseness,
inconvenience of attending for treatment, not enough
information about disease and its treatment, inadequate
support, unable to care for self, difficulty swallowing,
vomiting, pain on swallowing, decreased appetite, headache.
They will therefore not be analysed in detail in this section.
The data scores and counts for the 14 most frequently
mentioned of the core symptoms are presented in Figure 1.
At the start of treatment 55% ofpatients selected tiredness as
a symptom; by the end of treatment the figure was 71%.
Anxiety seemed to diminish as a problem: 62% of patients
mentioned anxiety at the beginning of treatment, but by the
end of treatment only 42% selected anxiety from the list of
problems. The data show a disparity in the relative ranking
of symptoms according to whether the symptoms are ranked
according to frequency or whether the ranking is by mean
score for each problem. Frequent symptoms do not
necessarily cause the most distress: the data on indigestion
illustrate this point. Over 35% of patients complained of
indigestion, but the mean score for indigestion was 1.96 and
it ranked only 11th in terms of the distress it apparently
caused.
Our primary aim was to estimate distress rather than
simply enumerate problems and the rest of the analysis is
therefore based on the scoring, rather than the counting, of
symptoms and problems.
Inspection of the data in Figure 1 suggests that there may
be significant changes in some of the core symptoms during
a course of radiotherapy. The only symptom to increase
significantly during treatment was tiredness: P by Wilcoxon
matched-pairs signed-rank test was 0.002. The following
symptoms were significantly less distressing by the end of
treatment: worry about effects of disease and treatment
upon the family (P=0.0003) and feeling anxious
(P=0.0002). The apparent changes in ability to concen-
trate, depression, taste, sweating and itch were not
statistically significant.
It was possible to derive, by simple addition, a total score
for the core symptoms for each individual patient. The data
in Table III show that there is no clear evidence that the total
distress caused by the core group of symptoms is worse in
any particular group of patients or at any particular time.
The open question was answered on 34 different occasions:
there were four problems which we had failed to include in
our original list. These items were subsequently added to the
inventory: increased sweating, headache, hot flushes, indiges-
tion.
Disease-specific symptoms and core symptoms in the different
groups ofpatients
Figure 2 shows the data for all symptoms which, on any
occasion, had an average score >2 for each group of
patients. The data are shown for the initial assessment (week
0), the end of treatment (week 3) and the first follow-up visit
(week 7). There were too few patients with lung cancer or
cancer of the head and neck for meaningful statistical
anlaysis.
The data from the patients with breast cancer showed
significant changes over time during the study period.
Tiredness significantly increased between the start of
treatment for breast cancer and the completion of radio-
therapy (P=0.009, Wilcoxon). It then decreased so that by
the first follow-up visit there was no significant difference
from the pretreatment baseline (P=0.9). There were no
statistically significant changes during the first 2 weeks of
treatment, but when the second week was compared with the
third week there was a significant increase in the scores for
tiredness (P=0.007, Wilcoxon). The sequential mean scores
and 95% confidence intervals were: week 0, 3.9 (2.9-4.9);
week 1, 4.77 (3.6-5.9); week 2, 5.25 (4.2-6.3); week 3, 6.85
(5.62-8.1); week 7, 4.2 (2.9-5.5). Other, more obviously
direct, effects of radiotherapy followed a similar pattern:
distress at not being able to wash properly increased between
week 0 and week 3 (P = 0.016) then decreased between week 3
and week 7 (P=0.004). Similarly, changes in the skin of the
breast increased during treatment (week 0 vs week 3,
P=0.0003) then appeared to decrease (week 0 vs week 7,
P=0.06). Similar, but statistically non-significant, patterns
were seen for heaviness of the treated breast and itching of
the treated skin.
Table II Correlation matrix for item scores: the values shown are for Kendall's tau with P-values for each
comparison in brackets
HAD HAD LASA




PPI 0.08 0.06 1
(0.21) (0.36)
HAD 0.39 0.25 0.01 1
anxiety (0.00001) (0.03) (0.86)
HAD 0.02 0.29 0.14 0.26 1
depression (0.72) (0.00001) (0.02) (0.00001)
LASA pain 0.06 0.13 0.79 0.04 0.18 1
(0.35) (0.22) (0.00001) (0.52) (0.004)
Pain 0.09 0.15 0.44 0.15 0.10 0.46 1
(0.13) (0.16) (0.00001) (0.02) (0.11) (0.00001)The distress caused by the following symptoms steadily
decreased between the initial assessment and the follow-up
visit: numbness (P=0.001, Wilcoxon); worry about effects of
disease and treatment upon family (P=0.0001, Wilcoxon);
feeling anxious (P=0.003, Wilcoxon). Using the non-
parametric test for trend only the change in worry about
family was significant (P=0.001).
The data on the AUC measurements in the patients with
breast cancer are shown in Table IV. The method used to
allow for missing data did not seem materially to affect the
interpretation of the results: the only significant change in
rank order according to the method used was for sleep
disturbances. The data cearly show, when taken in
conjunction with Figure 2, the importance of not relying on
a single time point for assessing the distress caused by
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Table HI Total symptom scores (means and confidence interval)
according to type of cancer and time of assessments- all avaliable
data have been used
Time Mean
Group (weeks) score 95% CI
Breast 0 41 32-49
3 36 31-47
7 30 22-38
Bronchus 0 40 31 -50
3 42 20-65
7 51 30-74
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Figure 1 (a) Mean score for the most important core symptoms (all patients). Week 0, before radiotherapy (U); week 3, during last week of radiotherapy (LI). (b) Percentage of patients mentioning symptoms as troublesome-the most prominent of the above core symptoms (all patients). Week 0, before radiotherapy, (U); week 3, during last week of radiotherapy, (El).
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Figure 2 (a) Data from patients with breast cancer: average score per symptom according to time of interview. Week 0, before
radiotherapy (U); week 3, during last week of radiotherapy (El); week 7, 4 weeks after the end of treatment. (_). (b) Data from
patients with lung cancer: average score per symptom according to time of interview. Week 0, before radiotherapy; week 3, during
last week of radiotherapy; week 7, 4 weeks after the end of treatment. (c) Data from patients with cancers of the head and neck:
average score per symptom according to time of interview. Week 0, before radiotherapy, week 3, during last week ofradiotherapy;
week 7, 4 weeks after the end of treatment.
particular symptoms. Difficulty concentrating, pain and sleep
disturbances emerge as significant causes of distress in these
patients when duration, as well as intensity, is taken into
account.
Discussion
The use of computerised self-assessment to sort and score
symptoms is clearly feasible. With 90% of assessments
completed in less than 15 min, we have an instrument that
could be used in routine clinical assessment for patients
treated with radiotherapy.
There is always the worry, in a project of this type, that
the combination of technology and the intrusion into
potentially sensitive areas might alienate patients, who might
then either refuse to complete the assessments or press
buttons at random in order to conclude the whole unpleasant
business as speedily as possible. Our results suggest that this
is not the case. Compliance was not a problem. The different,
and appropriate, patterns of symptomatic distress in the three
groups of patients suggest that the patients' responses were
not produced at random and were a reasonable guide to what
they were experiencing. Capturing the data was not a
problem; the interpretation of the data, teasing out its true
meaning, is much less straightforward.
The data from patients with lung cancer and cancers ofthe
head and neck are too limited to permit any detailed
conclusions to be drawn. Their main usefulness is to
demonstrate that the patterns of response elicited are in
accordance with prior expectation.
The data, from all 110 patients, on core symptoms confirm
previous observations (Smets, 1993; Lamszus et al., 1994;
Table IV Data on the area under the curve measurements (for
details of calculations, see text), data is from patients with breast
cancer only
Complete data Missing data
Problem sets only points at zero Imputed data
Tired 45 (33-57) 28 (22-33) 39 (34-44)
Numbness 39 (26-51) 23 (17-28) 29 (24-34)
Family worry 30 (15-43) 18 (13-24) 24 (18-31)
Work 30 (19-42) 19 (13-24) 26 (20-32)
Breast pain 29 (16-43) 16 (11-18) 22 (17-28)
Feeling anxious 25 (14-35) 15 (11-18) 20 (16-24)
Difficulty 25 (11-38) 14 (9-18) 19 (13-25)
concentrating
Breast 25 (13-37) 12 (8-17) 17 (12-22)
heaviness
Sleep 24 (12-36) 18 (14-23) 25 (20-30)
difficulties
Pain 23 (12-34) 12 (8-15) 17 (12-21)
Washing 22 (11-33) 14 (9-18) 17 (12-23)
Itch 22 (11-33) 11 (6-14) 14 (10-19)
Wallace et al., 1993; Irvine et al., 1994; Maraste et al., 1992).
Patients starting a course of radiotherapy mention anxiety,
worry about the effects of their disease and its treatment
upon their families, and problems related to work as being
significant concerns. At the end of treatment they are less
distressed by feeling anxious and are significantly more tired.
The question of tiredness in pateints being treated for
cancer is complex and has many aspects, both physical and
psychological. There are clearly genuine physical reasons for
increased tiredness during treatment-the strain of unaccus-
tomed daily travel (Junor et al., 1992), the metabolicMeasuring distress from radical radiotherapy
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demands of regenerating tissues. Psychological factors, are,
however, also important: over 40 years ago, Court Brown
(1953) noted that patients treated by sham irradiation
complained of feeling tired. Greenberg et al. (1992) have
described a pattern of an initial decrease, followed by an
increase, in tiredness during radiotherapy. We were unable to
confirm this observation: our data show a steady increase
during treatment, with the major impact being during the
final week of treatment.
Simply asking patients whether they feel tired is a
relatively crude measure. More precise measurements would
undoubtedly be possible with a more specialised instrument
such as the Multidimensional Fatigue Inventory (Smets et al.,
1995). Unfortunately, although the frequency and severity of
tiredness as a symptom in irradiated patients has been well
described, little specific treatment seems to be available.
Patients should at least be warned what to expect and advised
to pace their lives accordingly (Graydon et al., 1995).
The patients with breast cancer had a significant number
of physical problems directly related to their surgery and
radiotherapy. Numbness of the axilla and inner arm was a
major problem. It improved steadily during the period of the
study but, even a month after the finish of radiotherapy, 2-3
months after surgery, was still a significant concern. Pain and
heaviness in the treated breast were also troublesome. The
impact of these problems was more clearly demonstrated
using the AUC measurements.
Patients were allowed to wash during and after treatment,
provided they did not use soap or deodorant and provided they
did not rub out their skin marks. In spite ofthis relatively, but
insufficiently, liberal policy, the inability to have a decent bath
was clearly upsetting. The time course ofitching in the treated
skin was in accordance with expectation-maximal during the
last week of treatment and settling thereafter. Adjuvant
treatment caused significant upset. Hot flushes and increased
sweating were consistent and distresssing problems.
The rank order of symptoms in terms of the distress
caused depended upon the timing of the assessment. Feeling
anxious and numbness of the axilla and arm were the
dominant problems at the start of the treatment; by the end
of treatment tiredness and numbness predominated; by the
first follow-up visit tiredness, sweating and breast discomfort
were the major causes of distress.
The AUC data, by and large, confirm the visual
impression given by the data in Figure 2. Sleep difficulties
fell in rank, and breast pain rose in rank, when AUC rather
than mean score was used as the measure of distress. The
interpretation and ranking of AUC measurements is not
simple. Although such measurements are clearly useful in
assessing the 'total' upset caused by an individual symptom
during the period of observation (Matthews et al., 1990) there
is, inevitably, oversimplification. A mildly troublesome, but
persistent, symptom might well have an AUC value equal to
that of a much more distressing problem of shorter duration.
We are still left with the question of which is worse: a bang
on the thumb with a hammer or persistent mild backache?
The information obtained from the patients with breast
cancer suggests that there is a number of ways in which we
might improve matters for patients treated with radiotherapy.
Preliminary explanation and advice about tiredness are
important. Patients might misinterpret tiredness related to
treatment as being caused by progression of their cancer and,
as a result, suffer unnecessary worry. We need to be more
vigilant about analgesia, the use of non-steroidal anti-
inflammatory drugs might well improve some of the breast
discomfort and heaviness that so obviously troubles patients.
Washing instructions should be less restrictive-particularly
since there is no evidence that normal washing makes skin
reactions worse (Campbell and Illingworth, 1992). The
symptoms produced by the endocrine effects of adjuvant
treatment may respond to low doses ofprogestagens (Loprinzi
et al., 1994)-there is no reason to withhold such treatment
from patients who are distressed by menopausal symptoms.
The feasibility of computerised self-assessment means that
it is possible to consider using the technique in the routine
evaluation of symptoms in patients treated with radiotherapy.
The 10 to 15 min required for each evaluation could easily be
accommodated within the normal waiting time for treatment.
The technology used in our study was relatively primitive: a
cheap laptop, a small black and white screen, no fancy
graphics. Nevertheless, the patients found the system
acceptable and easy to use. The use of colour, touch-
sensitive screens and more attractive graphics might make the
approach even more acceptable for routine use.
There are several possible roles for this type of assessment
technique in clinical radiotherapy. In clinical studies
comparing schedules of fractionation the treatment-related
morbidity may be the main outcome of interest. Comparison
of patients' subjective distress during treatment would be
extremely useful adjunct to more traditional objective
measures. Computerised self-assessment could play a similar
role in comparisons and audit of supportive care regimens-
the rapid acquisition of data that is both subjective and
quantitative is crucial to such studies.
The assessment tool described here in no way attempts to
measure overall quality of life (QOL). It is focused quite
specifically on the problems and concerns associated with
attendance for treatment with radiotherapy. Future studies
should include comparison with a standard QOL measure,
such as the EORTC questionnaire (Aaronson et al., 1993). In
this way we might be able to gauge more accurately the
impact of radiotherapy-associated symptoms upon overall
QOL. A further development would be to do as we have
done for the HAD scale and to computerise the QOL
instruments themselves.
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Not enough support from family and friends
Feeling bad-tempered or irritable
The inconvenience of attending hospital
Unable to work or perform my usual activities
Hoarse voice











Pain in the breast
Swelling of the arm or hand
Pain in the nipple
Numbness in the armpit or arm
Heavy feeling in the breast
Discomfort in the skin of treated breast
Having to have blue marks on the skin
Worry about the possible need for additional treatment
(e.g. tamoxifen or chemotherapy)
Itching of the skin
Gain in weight
Not being able to wash properly
Head and neck patients only
Sore mouth or tongue
Unable to eat properly
Itching of the skin
Not being able to wash or shave properly
People having difficulty understanding what I'm saying
Dry mouth
Being immobilised in shell for treatment
Lung cancer patients only
Coughing up blood
Short of breath at rest
Short of breath on walking
Short of breath on stairs
Chest pain
Pain in the arm or shoulder





Supplementary questions (all patients)
LASA pain
Please indicate how much pain you have had over the past 24hours
no pain unbearable pain
McGill PPI
How would you describe your pain over the past 24 hours?
No pain
Mild pain
Discomforting pain
Distressing pain
Horrible pain
Excruciating pain